Shots:
The US FDA has cleared an IND application to initiate the P-I (ERASER) trial evaluating the safety, PK & preliminary efficacy of ATG-017 + nivolumab for advanced solid tumors
The results showed that the combination of an ERK1/2 inhibitor & an ICI worked synergistically to provide improved efficacy in preclinical ICI-resistant in vivo mice models
ATG-017 is an oral, potent & selective small molecule ERK1/2 inhibitor & was approved in Australia & the US to enter clinical studies for advanced solid tumors or hematologic malignancies. The preclinical results showed the combination of ATG-017 & atezolizumab rendered “cold” tumors “hot” in an aggressive immune checkpoint-resistant murine cancer model
Ref: Antengene | Image: Antengene
